Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: Relationship to virologic response

Clinical Infectious Diseases

Volumn 33, Issue 3, 2001, Pages 386-392

  Duong, Michel ^a   Piroth, Lionel ^a   Peytavin, Gilles ^a   Forte, Fabien ^a   Kohli, Evelyne ^a   Grappin, Michale ^a   Buisson, Marielle ^a   Chavanet, Pascal ^a   Portier, Henri ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEGALOCYTOSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; VIROLOGY;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; VIRAL LOAD;

EID: 0034920479     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/321876     Document Type: Article

References (34)

1. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy
2. Virological failure and adherence to antiretroviral therapy in HIV-infected patients
3. Measuring HIV treatment adherence in clinical practice
4. Drug monitoring of antiretroviral therapy for HIV-1 infection: Method of validation and results of a pilot study
5. The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker
6. Toxicity, efficacy, plasma drug concentration and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir
7. Definition and measurement of adherence to antiretroviral drugs in HIV-1-infected patients
8. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMScaps
9. Determination of nelfinavir, a potent HIV protease inhibitor, and its active metabolite M8 in human plasma by high-performance liquid chromatography with photodiode-array detection
10. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography
11. Determination of L-735 524, a human immunodeficiency virus protease inhibitor, in plasma and urine via high-performance liquid chromatography with column switching
12. A comparison of bid and tid dosing of nelfinavir when given in combination with stavudine (d4T) and lamivudine (3TC) for up to 48 weeks
13. US prescribing information: Norvir
14. Pilot study of bid and tid combinations of saquinavir-SGC (S), delavirdine (D), zidovudine (ZDV) and lamivudine (3TC) as initial therapy: Pharmacokinetic (PK) interaction between S-SGC and D
15. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy
16. 1993 Revised classification system for HIV infection and expanded surveillance of definition for AIDS among adolescents and adults
17. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072 Study Team)
18. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease
19. Adherence and effectiveness of protease inhibitors in clinical practice
20. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients
21. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
22. Adherence to combination antiretroviral therapy assessed by anonymous patient self-report
23. Electronic adherence assessment versus self-report in HIV-infected individuals
24. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
25. Antiretroviral medication compliance in patients with AIDS
26. Monitoring adherence to HIV therapy
27. Hyperbilirubinemia in patients treated with indinavir
28. Uric acid and didanosine compliance in AIDS clinical trials: An analysis of AIDS Clinical Trials Group protocols 116A and 116B/117
29. Changing etiology of macrocytosis: Zidovudine as a frequent causative factor
30. Causes of macrocytosis in HIV-infected patients not treated with zidovudine. Swiss HIV Cohort Study
31. Adherence to zidovudine (AZT) among HIV-infected methadone patients: A pilot study of supervised therapy and dispensing compared to usual care
32. Stavudine induced macrocytosis
33. Stavudin-induced macrocytosis during therapy for human immunodeficiency virus infection